More than half of patients achieved a ≥15 letter gain, with additional benefit observed in the top dose levels in the U.S. 48 Proportion of ≥15 letter gainers Patients , % 38 62 54 58 0 20 40 60 80 100 U.S. 2.5 mg (n=13) U.S. 5 mg (n=13) U.S. 10 mg (n=13) Asia Pooled (n=12) U.S. Asian Cohort Final results of the APEX study in MESI. Includes patients in the per protocol set that completed the Week 4 visit and met all the eligibility criteria. US: Excludes one patient in the 5 mg dose that discontinued treatment before Week 4, and one patient in the 10 mg dose with a significant epiretinal membrane at baseline (exclusion criterion). Asian cohort: excludes one patient with a significant epiretinal membrane at baseline (exclusion criterion).